Hunter Cliffton Spencer

Dr. Hunter Cliffton Spencer

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
KMKatherine Mackey
Katherine Mackey
CAChelsea K. Ayers
Chelsea K. Ayers
KKKarli K. Kondo
Karli K. Kondo
SSSomnath Saha
Somnath Saha
SAShailesh M. Advani
Shailesh M. Advani
DKDevan Kansagara
Devan Kansagara
Data suggest that impacts of COVID-19 differ among U.S. racial/ethnic groups. This systematic review evaluates racial/ethnic disparities in SARS-CoV-2 infection rates and COVID-19 outcomes, factors... Background: Data suggest that the effects of coronavirus disease 2019 (COVID-19) differ among U.S. racial/ethnic groups. Purpose: To evaluate racial/ethnic disparities in severe acute respiratory s...

13 June 2020 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
HSHunter Cliffton Spencer
Hunter Cliffton Spencer
RWRiana Wurzburger
Riana Wurzburger

6 September 2024 in Journal of Substance Use and Addiction Treatment
Verified
Journal Article
Closed access
HSHunter Cliffton Spencer
Hunter Cliffton Spencer
GLGillian Leichtling
Gillian Leichtling
JBJane Babiarz
Jane Babiarz
CFChristopher B. Fox
Christopher B. Fox
MHMegan Herink
Megan Herink
PKP. Todd Korthuis
P. Todd Korthuis

Verified
Journal Article
Open access
PDF file
TSThomas J Stopka
Thomas J Stopka
RNRobin M. Nance
Robin M. Nance
LMLyndsey Sarah Mixson
Lyndsey Sarah Mixson
HSHunter Cliffton Spencer
Hunter Cliffton Spencer
JTJudith I Tsui
Judith I Tsui
PFPeter D. Friedmann
Peter D. Friedmann
Limited research has examined the possible synergistic interrelationships between serious bacterial infections (SBIs) of the heart (i.e., endocarditis), bone, spine, brain, or joints (e.g., osteomylelitis) and hepatitis C virus (HCV) infections. We examined whether syndemic interactions existed between SBI, HCV, and substance-use-related factors in rural communities, hypothesizing that injection-mediated risks elevated the likelihood for both SBIs and HCV infections, which could be exacerbated by synergistic biological–biological or biological and social interactions. We calculated the prevalence ratios (PRs) of past-year SBI associated with each risk factor in separate models. Effect modification among significant risk factors was assessed using multiplicative interaction. Among 1936 participants, 57% were male and 85% White, with a mean age of 36 years. Eighty-nine participants (5%) reported hospitalization for an SBI in the year prior to the survey. More than half tested HCV-antibody-positive (58%); 62 (5.6%) of the participants with a positive HCV antibody result reported past-year hospitalization with an SBI. Injection behaviors were correlated with other SBI risk factors, including multiple injections in the same injection event (MIPIE), injection equipment sharing, and fentanyl use. In adjusted models, MIPIE (PR: 1.79; 95% confidence interval [CI]: 1.03, 3.11) and fentanyl use (PR: 1.68; 95% CI: 1.04, 2.73) were significantly associated with past-year SBI. Our analyses pointed to co-occurring epidemics of SBI and HCV, related to the cumulative health effects of fentanyl use contributing to frequent injections and MIPIE. Both the SBI and HCV epidemics present public health challenges and merit tailored interventions.

22 March 2023 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
HSHunter Cliffton Spencer
Hunter Cliffton Spencer
JBJane Babiarz
Jane Babiarz
TMTim W Menza
Tim W Menza
Background: Pre-Exposure Prophylaxis (PrEP) to prevent transmission of human immunodeficiency virus (HIV) among people who inject drugs (PWID) has demonstrated efficacy yet awareness of PrEP among PWID is low. Methods: 2018 National Behavioral Health Survey data from the Portland, Oregon metropolitan statistical area was analyzed with chi-squared tests and generalized linear models to determine correlates of PrEP awareness among PWID. Results: 80% of the sample had at least one indication for PrEP and 15% of the sample was aware of PrEP. Factors associated with higher PrEP awareness were: higher education level (PR = 1.083, CI = 1.018–1.153, p = .012), reporting transactional sex (PR = 1.154, CI = 1.019–1.307, p = .024), and men who have sex with men reporting condomless sex (PR = 1.376, CI = 1.081–1.752, p = .010). Lack of a usual source of care (PR = 0.884, CI = 0.824–0.949, p < .001) was negatively associated with PrEP awareness. Conclusions: Interventions to increase PrEP awareness need to target groups with particularly low awareness and be delivered in settings accessible to PWID.

13 September 2024 in Viruses
Verified
Journal Article
Open access
PDF file
HSHunter Cliffton Spencer
Hunter Cliffton Spencer
DGDevin Gregoire
Devin Gregoire
GLGillian Leichtling
Gillian Leichtling
MHMegan Herink
Megan Herink
ASAndrew Seaman
Andrew Seaman
RCRyan Cook
Ryan Cook
Hepatitis C (HCV) treatment for people who use drugs (PWUD) decreases injection drug use and injection equipment sharing. We examined changes in injection drug use and injection equipment sharing following HCV treatment in a randomized trial comparing peer-assisted telemedicine for HCV treatment (TeleHCV) versus peer-assisted usual care in rural PWUD. We hypothesize that TeleHCV reduces risky behaviors and peers facilitate this change. We used mixed-effects logistic regression to describe participant-level (n = 203) associations between both injection drug use and injection equipment sharing and randomized groups, frequency of peer contact, HCV treatment initiation, HCV cure, and time. Risky behaviors were surveyed at baseline and 12 and 36 weeks after HCV treatment completion. Injection drug use declined more over time in TeleHCV participants vs. control at 12 weeks (adjusted odds ratio [aOR] = 0.42, 95% CI 0.20–0.87, p = 0.02) and 36 weeks (aOR = 0.48, 95% CI 0.21–1.08, p = 0.076). Injection drug use decreased more with a greater number of peer interactions, with reductions among participants in the 3rd quartile exceeding those in the 1st quartile of peer interactions at 12 weeks (aOR = 0.75, 95% CI 0.57–0.99, p = 0.04). Similarly, injection equipment sharing decreased over time, with reductions among participants in the 3rd quartile exceeding those in the 1st quartile of peer interactions at 36 weeks (aOR = 0.08, 95% CI 0.01–0.97, p = 0.047). Peer-assisted telemedicine for HCV treatment decreases injection drug use and injection equipment sharing; peers contribute to this effect.